Journal of Clinical Oncology
Articles in this Issue
Genomic differences between primary and metastatic melanoma: Insights from AACR GENIE.
e21585 Background: Melanoma is a highly aggressive malignancy that is characterized by a complex and heterogeneous genomic...
FALCON-Lung: Evolving global real-world treatment choices and outcomes for metastatic NSCLC in different patient populations.
1553 Background: Despite rapid global adoption of immune checkpoint inhibitors (ICI) for metastatic non–small cell lung ca...
Patient-reported telehealth experiences, medication adherence, symptom burden, and financial toxicity: A survey-based study.
e23258 Background: Telehealth may reduce geographic and logistical barriers to oncology care. Data on real-world uptake an...
Effects of SGLT2 inhibitor dapagliflozin on anticancer resistance and alpelisib- and fulvestrant-induced cardiomyocyte injury under hyperglycemic conditions.
1091 Background: Activating PIK3CA mutations occur in approximately 40% of hormone receptor–positive (HR+)/HER2-negative b...
Some features of the energy metabolism of primary cell cultures of sarcomas.
e23540 Background: Cellular bioenergetic profiles are critical determinants of tumor biology and can vary significantly be...
RNA-based next-generation sequencing for identification of clinically actionable gene fusions missed by conventional cytogenetics in hematologic malignancies.
e18534 Background: Accurate detection of genomic alterations with diagnostic, prognostic, and therapeutic relevance is cri...
Preclinical data of IBI3028, the first clinical-stage bispecific dual-payload ADC, targeting EGFR/c-MET–positive advanced solid tumors.
e15020 Background: Acquired and intrinsic resistance to topoisomerase-1i ADCs are emerging as key unmet need, driven by he...
Clinical performance of novel exosomal liquid RNA biopsy assay in breast cancer segment.
e12561 Background: Exosomal RNA captures dynamic tumor biology and may overcome limitations of tissue biopsy and imaging,...
Real-world outcomes and subsequent treatment utilization following anti-B-cell maturation antigen antibody-drug conjugate exposure in patients with multiple myeloma.
e19503 Background: The anti-B-cell maturation antigen (BCMA) antibody-drug conjugate (ADC) belantamab mafodotin is approve...
Refining clinical trial eligibility for minimal residual disease in patients with colorectal cancer: The MD Anderson INTERCEPT experience.
3609 Background: Detection of circulating tumor DNA (ctDNA) is prognostic for recurrence after completion of curative-inte...
Real-world prevalence, co-occurrence, and descriptive analysis of ESR1 and PIK3CA mutations in metastatic breast cancer: A retrospective analysis.
e13060 Background: The approval of alpelisib for PIK3CA-mutated breast cancer in 2019 and elacestrant for ESR1-mutated cas...
Global context matters: Knowledge distillation–enabled ResNet modeling for noninvasive stratification of adrenal tumors.
e13681 Background: Adrenal tumors are increasingly detected as incidental findings on cross-sectional imaging, yet accurat...
Prevalence and clinical relevance of Janus kinase 2 (JAK2) mutation in myelodysplastic/myeloproliferative neoplasm (MDS/MPN) overlap syndromes.
e18586 Background: MDS/MPN is a group of myeloid malignancies characterized by overlapping dysplastic and proliferative fe...
Use of <i>NECTIN4</i> expression inferred from circulating chromatin to predict response and survival to enfortumab vedotin (EV) in metastatic urothelial carcinoma.
4588 Background: APEX (Associating Plasma Epigenomics with eXpression) is a machine-learning framework that infers genome-...
Racial disparities in cancer-specific survival of estrogen receptor–negative, progesterone receptor–positive breast cancer: A focus on the American Indian population.
e12708 Background: Estrogen receptor–negative, progesterone receptor–positive (ER−/PR+) breast cancer is a raresubtype (2–...
Radiotherapy and EGFR inhibition for high-risk cutaneous squamous cell carcinoma in immunosuppressed patients.
e21562 Background: Immunosuppression (IS) is a recognized risk factor for cutaneous squamous cell cancer (cSCC) incidence,...
The efficacy and safety of azvudine (FNC) in phase 1 investigator-initiated study in patients with advanced solid tumors.
3018 Background: Azvudine has been approved in China for treatment of AIDS and COVID-19. Serial preclinical studies demons...
Double lung transplantation in patients with recent history of malignancy.
e20773 Background: Recent history of malignancy usually within five years is a contraindication for double lung transplant...
Efficacy of datopotamab deruxtecan after trastuzumab deruxtecan in metastatic hormone receptor–positive HER2-negative breast cancer: A real-world study.
e13040 Background: Datopotamab deruxtecan (Dato-DXd) and trastuzumab deruxtecan (T-DXd) are antibody–drug conjugates used...
National trends and demographic disparities in mortality among adults with hepatocellular carcinoma and diabetes mellitus in the United States (1999–2020).
e16168 Background: Hepatocellular carcinoma (HCC) is a growing public health concern in the United States, particularly am...
Initial treatment modality and recurrence in non-metastatic leiomyosarcoma: A retrospective cohort study.
e23555 Background: Leiomyosarcoma (LMS) is an aggressive malignancy comprising 10–20% of soft tissue sarcomas, with high r...
Induction toripalimab and chemotherapy for organ preservation in locally advanced laryngeal and hypopharyngeal cancer: 3-year follow-up of the INSIGHT study.
6086 Background: This phase II study evaluated the efficacy and larynx-preservation potential of induction chemotherapy co...
Trends and disparities in liver cancer mortality among adults with metabolic disorders in the United States, 1999–2023.
e16229 Background: Liver cancer is a leading cause of cancer-related mortality worldwide, with rising incidence linked to...
Quantitative baseline ctDNA as a prognostic biomarker in metastatic urothelial cancer.
e16572 Background: Detectable circulating tumor DNA (ctDNA) in patients with metastatic urothelial cancer (mUC) is associa...
Neurosensory deficits and functional outcomes in childhood cancer survivors: A report from the Childhood Cancer Survivor Study (CCSS).
10046 Background: Survivors of childhood cancer are at risk for neurosensory deficits secondary to their disease and treat...